Literature DB >> 23360144

Cytochrome P450-activated prodrugs.

Paul R Ortiz de Montellano1.   

Abstract

A prodrug is a compound that has negligible, or lower, activity against a specified pharmacological target than one of its major metabolites. Prodrugs can be used to improve drug delivery or pharmacokinetics, to decrease toxicity, or to target the drug to specific cells or tissues. Ester and phosphate hydrolysis are widely used in prodrug design because of their simplicity, but such approaches are relatively ineffective for targeting drugs to specific sites. The activation of prodrugs by the cytochrome P450 system provides a highly versatile approach to prodrug design that is particularly adaptable for targeting drug activation to the liver, to tumors or to hypoxic tissues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360144      PMCID: PMC3697796          DOI: 10.4155/fmc.12.197

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  97 in total

1.  Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.

Authors:  Thien-An Nguyen; Marina Tychopoulos; Florence Bichat; Clothilde Zimmermann; Jean-Pierre Flinois; Monique Diry; Emelie Ahlberg; Marcel Delaforge; Laurent Corcos; Philippe Beaune; Patrick Dansette; François André; Isabelle de Waziers
Journal:  Mol Pharmacol       Date:  2008-01-22       Impact factor: 4.436

2.  Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

Authors:  K Ikeda; K Yoshisue; E Matsushima; S Nagayama; K Kobayashi; C A Tyson; K Chiba; Y Kawaguchi
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

3.  Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase.

Authors:  Janelle Y Saulter; Joseph R Kurian; Lauren A Trepanier; Richard R Tidwell; Arlene S Bridges; David W Boykin; Chad E Stephens; Mariappan Anbazhagan; James Edwin Hall
Journal:  Drug Metab Dispos       Date:  2005-08-30       Impact factor: 3.922

4.  Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.

Authors:  T Komatsu; H Yamazaki; N Shimada; S Nagayama; Y Kawaguchi; M Nakajima; T Yokoi
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

5.  The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices.

Authors:  R A Stearns; R R Miller; G A Doss; P K Chakravarty; A Rosegay; G J Gatto; S H Chiu
Journal:  Drug Metab Dispos       Date:  1992 Mar-Apr       Impact factor: 3.922

6.  Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.

Authors:  Joseph R Mace; Mary L Keohan; Heinz Bernardy; Klaus Junge; Georg Niebch; Peter Romeis; Aangelika Thoma; Thomas Wagner; Udo Mueller; George Demetri; Laurence H Baker
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

Review 7.  Cytochrome P450 pharmacogenetics and cancer.

Authors:  C Rodriguez-Antona; M Ingelman-Sundberg
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 8.  CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

Authors:  D L Boger; D S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

Review 9.  Mechanisms of cytochrome P450 induction.

Authors:  Leslie M Tompkins; Andrew D Wallace
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

10.  Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Authors:  Jian-Xin Duan; Hailong Jiao; Jacob Kaizerman; Timothy Stanton; James W Evans; Leslie Lan; Gustavo Lorente; Monica Banica; Don Jung; Jinwei Wang; Huaiyu Ma; Xiaoming Li; Zhijian Yang; Robert M Hoffman; W Steve Ammons; Charles P Hart; Mark Matteucci
Journal:  J Med Chem       Date:  2008-02-08       Impact factor: 7.446

View more
  24 in total

Review 1.  Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.

Authors:  Yeo-Jung Kwon; Sangyun Shin; Young-Jin Chun
Journal:  Arch Pharm Res       Date:  2021-01-23       Impact factor: 4.946

2.  Enzyme/Prodrug Systems for Cancer Gene Therapy.

Authors:  Obeid M Malekshah; Xuguang Chen; Alireza Nomani; Siddik Sarkar; Arash Hatefi
Journal:  Curr Pharmacol Rep       Date:  2016-10-19

3.  Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.

Authors:  Carlota Oleaga; Anne Riu; Sandra Rothemund; Andrea Lavado; Christopher W McAleer; Christopher J Long; Keisha Persaud; Narasimhan Sriram Narasimhan; My Tran; Jeffry Roles; Carlos A Carmona-Moran; Trevor Sasserath; Daniel H Elbrecht; Lee Kumanchik; L Richard Bridges; Candace Martin; Mark T Schnepper; Gail Ekman; Max Jackson; Ying I Wang; Reine Note; Jessica Langer; Silvia Teissier; James J Hickman
Journal:  Biomaterials       Date:  2018-08-04       Impact factor: 12.479

4.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

Review 5.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 6.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

7.  CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.

Authors:  Hamid Zia; Graeme I Murray; Carrie A Vyhlidal; J Steven Leeder; Ahmed E Anwar; Marilyn M Bui; Atif A Ahmed
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

8.  Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking.

Authors:  Adrien Guillot; Tianyi Ren; Tony Jourdan; Robert J Pawlosky; Elaine Han; Seung-Jin Kim; Li Zhang; George F Koob; Bin Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

Review 9.  The safety evaluation of food flavouring substances: the role of metabolic studies.

Authors:  Robert L Smith; Samuel M Cohen; Shoji Fukushima; Nigel J Gooderham; Stephen S Hecht; F Peter Guengerich; Ivonne M C M Rietjens; Maria Bastaki; Christie L Harman; Margaret M McGowen; Sean V Taylor
Journal:  Toxicol Res (Camb)       Date:  2018-03-28       Impact factor: 3.524

10.  Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.

Authors:  Tyler B Hughes; Na Le Dang; Ayush Kumar; Noah R Flynn; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-09-16       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.